Associations Between Amplification (1q) and Prior Cancer in a Real-World De Novo Myeloma Cohort. Issue 1 (4th January 2021)

• Record Type: Journal Article
• Authors: Lamont, Elizabeth B; Yee, Andrew J; Goldberg, Stuart L; Siegel, David S; Norden, Andrew D
• Is Part Of: JNCI cancer spectrum. Volume 5:Issue 1(2021)
• Publication Date: 2021-01-04
• DOI: 10.1093/jncics/pkaa111
• Languages: English
• ISSNs: 2515-5091

Abstract

Abstract: Genomic biomarkers inform treatment in multiple myeloma (MM), making patient clinical data a potential window into MM biology. We evaluated de novo MM patients for associations between specific MM cytogenetic patterns and prior cancer history. Analyzing a MM real-world dataset, we identified a cohort of 1769 patients with fluorescent in situ hybridization cytogenetic testing at diagnosis. Of the patients, 241 (0.14) had histories of prior cancer(s). Amplification of the long arm of chromosome 1 [amp(1q)] varied by prior cancer history (0.31 with prior cancer vs 0.24 without; 2-sided P = .02). No other MM translocations, amplifications, or deletions were associated with prior cancers. Amp(1q) and cancer history remained strongly associated in a logistic regression adjusting for patient demographic and disease attributes. The results merit follow-up regarding carcinogenic treatment effects and screening strategies for second malignancies. Broadly, the findings suggest that analyses of patient-level phenotypic-genomic real-world dataset may accelerate cancer research through hypothesis-generating studies.